About brigimadlin
Mechanism of action
Brigimadlin is a potent, oral MDM2-p53 antagonist that blocks the interaction between MDM2 and p53. This prevents MDM2 from inactivating p53, thereby restoring p53 function.1 Stabilization of p53 leads to TP53 target gene induction that subsequently leads to cell cycle arrest or apoptosis in tumor cells with TP53 wild type status.1-3
Mechanism of action: inhibition of the interaction between MDM2 and p532-7
MDM2, murine double minute 2; wt, wild type.
Watch the brigimadlin mechanism of action animation
Combination therapy
Checkpoint inhibitors, such as anti–PD-1, may benefit patients with certain sarcoma subtypes, such as undifferentiated pleomorphic sarcoma (UPS), leiomyosarcoma (LMS), and liposarcoma (LPS).6,8
The immunomodulatory properties of MDM2 inhibitors make them suitable combination partners for PD-1 inhibitors.8,9
LoRusso P, et al. Cancer Discov. 2023;13:1802-1813.
Schöffski P, et al. ASCO 2022. Poster TPS11586.
Rudolph D, et al. AACR 2018. Abstract 4868.
Zhao Y, et al. Acta Biochim Biophys Sin (Shanghai). 2014;46(3):180–9.
Marei HE, et al. Cancer Cell Int. 2021;21(1):703.
LoRusso P, et al. ASCO 2021. Poster 3016.
Wang HQ, et al. Cancer Res. 2008;78(Suppl. 13): Abstract 5560.
Nag S, et al. J Biomed Res. 2013;27(4):254–71.
Guo G, et al. Cancer Res. 2017;77:2292–305.